Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,676 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression.
Koyama K, Ishikawa H, Abe M, Shiose Y, Ueno S, Qiu Y, Nakamaru K, Murakami M. Koyama K, et al. Among authors: murakami m. PLoS One. 2022 May 3;17(5):e0267027. doi: 10.1371/journal.pone.0267027. eCollection 2022. PLoS One. 2022. PMID: 35503762 Free PMC article.
A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization.
Hashimoto Y, Koyama K, Kamai Y, Hirotani K, Ogitani Y, Zembutsu A, Abe M, Kaneda Y, Maeda N, Shiose Y, Iguchi T, Ishizaka T, Karibe T, Hayakawa I, Morita K, Nakada T, Nomura T, Wakita K, Kagari T, Abe Y, Murakami M, Ueno S, Agatsuma T. Hashimoto Y, et al. Among authors: murakami m. Clin Cancer Res. 2019 Dec 1;25(23):7151-7161. doi: 10.1158/1078-0432.CCR-19-1745. Epub 2019 Aug 30. Clin Cancer Res. 2019. PMID: 31471314
Pan-cancer gene expression analysis of tissue microarray using EdgeSeq oncology biomarker panel and a cross-comparison with HER2 and HER3 immunohistochemical analysis.
Inaki K, Shibutani T, Maeda N, Eppenberger-Castori S, Nicolet S, Kaneda Y, Koyama K, Qiu Y, Wakita K, Murakami M. Inaki K, et al. Among authors: murakami m. PLoS One. 2022 Sep 22;17(9):e0274140. doi: 10.1371/journal.pone.0274140. eCollection 2022. PLoS One. 2022. PMID: 36137139 Free PMC article.
Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells.
Okajima D, Yasuda S, Maejima T, Karibe T, Sakurai K, Aida T, Toki T, Yamaguchi J, Kitamura M, Kamei R, Fujitani T, Honda T, Shibutani T, Muramatsu S, Nakada T, Goto R, Takahashi S, Yamaguchi M, Hamada H, Noguchi Y, Murakami M, Abe Y, Agatsuma T. Okajima D, et al. Among authors: murakami m. Mol Cancer Ther. 2021 Dec;20(12):2329-2340. doi: 10.1158/1535-7163.MCT-21-0206. Epub 2021 Aug 19. Mol Cancer Ther. 2021. PMID: 34413126 Free PMC article.
Proton Beam Therapy for Intrahepatic Cholangiocarcinoma: A Multicenter Prospective Registry Study in Japan.
Mizumoto M, Terashima K, Makishima H, Suzuki M, Ogino T, Waki T, Iwata H, Tamamura H, Uchinami Y, Akimoto T, Okimoto T, Iizumi T, Murakami M, Katoh N, Maruo K, Shibuya K, Sakurai H. Mizumoto M, et al. Among authors: murakami m. Liver Cancer. 2023 Jul 24;13(2):161-168. doi: 10.1159/000531376. eCollection 2024 Apr. Liver Cancer. 2023. PMID: 38751552 Free PMC article.
5,676 results